Company intelligence / Profile preview

Beijing Kanghong Biopharmaceutical

Beijing, Beijing, Chinaen.cnkh.com ↗

Ownership: Private
Employees: ~4462
Development stage: Phase 1

Overview

Beijing Kanghong Biopharmaceutical is an active Chinese biotech/pharma company focused on developing innovative biological drugs including monoclonal antibodies and gene therapies. It operates commercial-scale GMP manufacturing facilities in Beijing designed to meet NMPA, EMA & FDA standards. The company has at least two known clinical-stage programs targeting cancer and autoimmune indications. It is a subsidiary of Chengdu Kanghong Pharmaceutical Group—a major publicly traded pharmaceutical group with global operations.

Therapeutic areas: OncologyDermatology
Modalities: Monoclonal antibodiesBiological productsGene therapy
Industry: Biotech

Drug pipeline

1 asset

KH-801

Beyond the preview

Go deeper on Beijing Kanghong Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kanghong Biopharmaceutical.

Explore the full profile